Advertisement
Clinical Trials
Subscribe to Clinical Trials

The Lead

Bristol-Myers Gets Positive EMA Opinion for Immunotherapy Drug, Opdivo

April 24, 2015 12:36 pm | by Stephanie Guzowski, Editor | Articles | Comments

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommended approval of Bristol-Myers Squibb’s Opdivo today for the treatment of melanoma. Read more..

Human Clinical Trials Planned for New Anti-Cancer Compound

April 23, 2015 8:55 am | by University of Auckland | News | Comments

Researchers developed a new anti-cancer compound that will advance to human phase two clinical...

AACR 2015: Pembrolizumab Comes Out on Top for Melanoma, Lung Cancer

April 22, 2015 10:33 am | by Stephanie Guzowski, Editor | Articles | Comments

At the AACR Annual Meeting 2015, immunotherapies, called PD-1 inhibitors, were front and center...

GW Pharmaceuticals Initiates Second Phase 3 Trial for Epidiolex

April 21, 2015 3:15 pm | News | Comments

This drug is intended for the treatment of Dravet syndrome. Read more...

View Sample

FREE Email Newsletter

Daily news and top headlines for drug research professionals

Isarna Initiates First-in-Human Phase I Trial for Drug to Treat Advanced Glaucoma

April 17, 2015 8:11 am | News | Comments

The trial will enroll approximately 24 - 30 patients. Read more...

Pfizer Breast Cancer Drug Shows Promising Results

April 16, 2015 2:19 pm | by Stephanie Guzowski, Editor | News | Comments

Pfizer said on Wednesday a late-stage trial of its treatment for advanced breast cancer, Ibrance, was stopped early after it met its primary goal of delaying disease progression. Read more...

A Patch for Peanut Allergies

April 9, 2015 11:56 am | by Bevin Fletcher, Associate Editor | News | Comments

French biopharmaceutical company DBV Technologies moves closer to bringing its peanut allergy patch to market, receiving Breakthrough Therapy Designation from the U.S. Food and Drug Administration as it prepares to launch its Phase 3 trial. Read more...

Advertisement

Risk of Breast, Ovarian Cancer May Differ By Type of BRCA1, BRCA2 Mutation: Study

April 8, 2015 12:51 pm | by UPenn | News | Comments

In a study involving more than 31,000 women with cancer-causing mutations in the BRCA1 or BRCA2 genes, researchers at the Basser Center for BRCA, the Abramson Cancer Center, and the Perelman School of Medicine at the University of Pennsylvania, identified mutations that are associated with significantly different risks of breast and ovarian cancers. Read more...

Personalized Melanoma Vaccines Marshal Immune Response

April 6, 2015 9:49 am | by Washington University in St. Louis | News | Comments

Personalized melanoma vaccines can be used to marshal a powerful immune response against unique mutations in patients’ tumors, according to early data in a first-in-people clinical trial at Washington University School of Medicine in St. Louis. Read more...

Experimental Ebola Vaccine Appears Safe, Prompts Immune Response

April 2, 2015 10:35 am | by NIH | News | Comments

An early-stage clinical trial of an experimental Ebola vaccine conducted at the National Institutes of Health (NIH) and the Walter Reed Army Institute of Research (WRAIR) found that the vaccine, called VSV-ZEBOV, was safe and elicited robust antibody responses in all 40 of the healthy adults who received it. Read more...

GeoVax HIV Vaccine Moves Forward

April 1, 2015 1:40 pm | News | Comments

GeoVax Labs, a biotechnology company developing human vaccines for Ebola and HIV, today announced that the HIV Vaccine Trials Network (HVTN) has assigned a trial number, HVTN 114, to the next clinical trial of its clade B preventive HIV vaccine candidate. Read more...

BioDelivery Sciences’ Pain Treatment Fails Study

March 30, 2015 3:46 pm | by Stephanie Guzowski, Editor | News | Comments

BioDelivery Sciences International Inc. said on Monday its pain drug for diabetic neuropathy failed to meet the primary goal in a Phase 3 clinical trial. Shares fell nearly 30 percent. Read more...

Advertisement

Integrative Approaches Key to Understanding Cancer and Developing Therapies

March 29, 2015 3:16 pm | by Moffitt Cancer Center | News | Comments

Researchers are using integrative approaches to study cancer by combining mathematical and computational modeling with experimental and clinical data. Read more...

Roseroot Shows Promise as Potential Depression Treatment Option

March 27, 2015 10:27 am | by Penn University | News | Comments

Rhodiola rosea (R. rosea), or roseroot, may be a beneficial treatment option for major depressive disorder (MDD), according to results of a study in the journal Phytomedicine. Read more...

HIV Replicates in Brain Earlier than Thought: Study

March 26, 2015 2:05 pm | by Stephanie Guzowski, Editor | News | Comments

A recent study, funded by the National Institutes of Health (NIH), highlights the importance of HIV screening and beginning antiretroviral therapy (ART) as early as possible. The analysis of cerebral spinal fluid (CSF), which illuminates brain chemical activity, showed that HIV can begin replicating in a patient’s brain as early as four months after infection. Read more...

Men’s Heart Disease Partly Due to Low Estrogen

March 26, 2015 8:52 am | by Cynthia Fox, Science Writer | Articles | Comments

One reason men have more heart disease than women is the very fact that they are men, reports Harvard University endocrinologist Evelyn Yu, M.D., MS.c. Both men’s higher testosterone levels and their lower estrogen levels, play a role. Read more...

Sanofi Announces Top-Line Results for Study of Lyxumia

March 19, 2015 4:32 pm | News | Comments

Full results will be presented at the American Diabetes Association 75th Scientific Sessions in Boston. Read more...

Advertisement

World-First Cancer Drugs Could Work in Larger Group of Patients

March 19, 2015 4:22 pm | by Institute of Cancer Research | News | Comments

A pioneering class of drugs that target cancers with mutations in the BRCA breast cancer genes could also work against tumors with another type of genetic fault. Read more...

Study Suggests Precision Medicine for Adrenal Cancer

March 18, 2015 10:57 am | by University of Michigan | News | Comments

Despite overall lack of success, small subset of patients responds to investigational drug. Read more...

Sickle Cell Drug Offers “Overwhelming” Gains as “Exciting” Stem Cell Trial Starts

March 16, 2015 3:58 pm | by Cynthia Fox, Science Editor | Articles | Comments

A clinical trial of the most common sickle cell anemia drug, hydroxyurea, was halted a year early this winter because of “overwhelming evidence of benefit,” reported University of Nebraska Medical Center pediatric researcher Stephen Obaro, M.D., Ph.D., in The Lancet. Read more...

Amgen's Cholesterol-Lowering Repatha Shows Positive Data

March 16, 2015 10:19 am | News | Comments

Amgen announced new detailed data from the Phase 3 YUKAWA-2 study evaluating Repatha (evolocumab), a novel investigational cholesterol-lowering medication, in Japanese patients with high cardiovascular risk and high cholesterol.  Read more...

Anti-Herpes Drug May Help Control HIV

March 13, 2015 1:56 pm | by Stephanie Guzowski, Editor | News | Comments

A drug that’s used to control herpes simplex virus 2 (HSV-2) could reduce levels of HIV in patients who do not have genital herpes, finds a National Institutes of Health (NIH) study. Read more...

Diabetes Drug Shown Not to Increase Heart Failure Risk

March 13, 2015 12:17 pm | by University of Connecticut | News | Comments

People with the most common form of diabetes can take the new drug Alogliptin without concern for an increased risk of heart failure or cardiovascular disease, according to research by a UConn cardiologist published in the British medical journal, The Lancet. Read more..

FDA Approves Pediatric Cancer Drug

March 11, 2015 4:24 pm | by Stephanie Guzowski, Editor | News | Comments

The U.S. Food and Drug Administration (FDA) has approved Unituxin (dinutuximab), part of a first-line therapy for high-risk neuroblastoma. Read more..                                  

Investigational Therapy Could Attack Cause of Sickle Cell Crises

March 3, 2015 11:47 am | News | Comments

Treatment for painful episodes of blood vessel obstruction in sickle cell anemia is currently limited to controlling pain, but an investigational therapy might be able to interfere with the underlying cause of these events, known as vaso-occlusion crises, researchers at Duke Medicine report. Read more...

Amgen Announces Results of Phase 3 Head-to-Head Study of Drugs for Multiple Myeloma

March 2, 2015 12:59 pm | News | Comments

Patients receiving one of the medications that was tested lived twice as long without disease progression. Read more...                       

Sanofi Gets FDA Approval for New Insulin Drug

February 26, 2015 12:06 pm | by Stephanie Guzowski, Editor | News | Comments

Sanofi announced late Wednesday that it received approval from the U.S. Food and Drug Administration (FDA) to sell its new insulin product Toujeo. The once-daily, long-acting basal insulin will help improve glycemic control in adults with type 1 and type 2 diabetes. Read more..

First Independent U.S. Psoriasis Registry Will Track Drug Safety

February 26, 2015 11:09 am | News | Comments

People with psoriasis and their health care providers will have the opportunity to participate in research that aims to improve treatments and disease outcomes when the first independent U.S. psoriasis registry begins recruiting patients in 2015. Read more...

Amgen: Positive Results for CKD Treatment

February 26, 2015 11:05 am | News | Comments

Amgen announced results from the head-to-head Phase 3 study comparing AMG 416 with cinacalcet for the treatment of secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease (CKD) receiving hemodialysis. Read more...

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading